| 产品描述: | Ensitrelvir (S-217622) fumarate is the first orally active non-covalent, non-peptidic, SARS-CoV-2 3CL protease inhibitor (IC50=13 nM)[1][2]. |
| 体外研究: |
Ensitrelvir fumarate 剂量依赖性地抑制 SARS-CoV-2 在小鼠肺内的复制[2]。 |
| 参考文献: |
1. McKimm-Breschkin JL, et al. COVID-19, Influenza and RSV: Surveillance-informed prevention and treatment - Meeting report from an isirv-WHO virtual conference. Antiviral Res. 2022;197:105227. 2. Yuto Unoh, et al. Discovery of S-217622, a Non-Covalent Oral SARS-CoV-2 3CL Protease Inhibitor Clinical Candidate for Treating COVID-19. bioRxiv 2022.01.26.477782. |
| 保存条件: |
-80°C 12个月; -20°C 6个月, 干燥 |
| 配置溶液浓度参考: |
|
1mg |
5mg |
10mg |
| 1 mM |
1.543 ml |
7.717 ml |
15.433 ml |
| 5 mM |
0.309 ml |
1.543 ml |
3.087 ml |
| 10 mM |
0.154 ml |
0.772 ml |
1.543 ml |
| 50 mM |
0.031 ml |
0.154 ml |
0.309 ml |
|
| 注意: |
部分产品我司仅能提供部分信息,我司不保证所提供信息的权威性,仅供客户参考交流研究之用。 |